DGX vs HCA
Quest Diagnostics Inc. and HCA Healthcare, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | DGX | HCA |
|---|---|---|
| Revenue | $11.0B | $75.6B |
| Net income | $992.0M | $6.8B |
| Gross margin | 33.2% | · |
| Net margin | 9.5% | 10.3% |
| Return on equity | 14.2% | · |
| Diluted EPS | $8.75 | $28.33 |
| Dividend / share | · | $2.88 |
| Payout ratio | 35.6% | 10.0% |
| Free cash flow | $1.4B | $7.7B |
| Equity | $7.2B | $-6.0B |
| Net debt / equity | 0.73× | · |
| Current ratio | 1.04× | 0.97× |
| Revenue CAGR 5y | 3.2% | 8.0% |
| Profit CAGR 5y | −7.1% | 12.6% |
HCA bills 6.9× the revenue of DGX, and keeps more of each dollar of revenue as profit (10.3% against 9.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | DGX | HCA |
|---|---|---|
| FY2025 | $11.0B | $75.6B |
| FY2024 | $9.9B | $70.6B |
| FY2023 | $9.3B | $65.0B |
| FY2022 | $9.9B | $60.2B |
| FY2021 | $10.8B | $58.8B |
| FY2020 | $9.4B | $51.5B |
| FY2019 | $7.7B | $51.3B |
| FY2018 | $7.5B | $46.7B |
| FY2017 | $7.4B | $43.6B |
| FY2016 | $7.2B | $41.5B |
Bottom line
| Fiscal year | DGX | HCA |
|---|---|---|
| FY2025 | $992.0M | $6.8B |
| FY2024 | $871.0M | $5.8B |
| FY2023 | $854.0M | $5.2B |
| FY2022 | $946.0M | $5.6B |
| FY2021 | $2.0B | $7.0B |
| FY2020 | $1.4B | $3.8B |
| FY2019 | $858.0M | $3.5B |
| FY2018 | $736.0M | $3.8B |
| FY2017 | $772.0M | $2.2B |
| FY2016 | $645.0M | $2.9B |
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$64,565,000,000 | HCA |
| FY2024 | −$60,731,000,000 | HCA |
| FY2023 | −$55,716,000,000 | HCA |
| FY2022 | −$50,350,000,000 | HCA |
| FY2021 | −$47,964,000,000 | HCA |
| FY2020 | −$42,096,000,000 | HCA |
| FY2019 | −$43,610,000,000 | HCA |
| FY2018 | −$39,146,000,000 | HCA |
| FY2017 | −$36,212,000,000 | HCA |
| FY2016 | −$34,276,000,000 | HCA |
| FY2014 | −$29,483,000,000 | HCA |
| FY2013 | −$27,036,000,000 | HCA |
| FY2012 | −$25,630,000,000 | HCA |
| FY2011 | −$22,290,000,000 | HCA |
| FY2010 | −$20,774,880,000 | HCA |
| FY2009 | −$19,320,757,000 | HCA |
HCA has reported the higher revenue in every one of these 16 fiscal years. The gap has widened since the earliest year compared.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −0.8 pp | HCA |
| FY2024 | −0.1 pp | HCA |
| FY2023 | +0.4 pp | DGX |
| FY2022 | −1.1 pp | HCA |
| FY2021 | +6.1 pp | DGX |
| FY2020 | +7.4 pp | DGX |
| FY2019 | +3.7 pp | DGX |
| FY2018 | +1.1 pp | DGX |
| FY2017 | +4.8 pp | DGX |
| FY2016 | +1.4 pp | DGX |
| FY2014 | +1.5 pp | DGX |
| FY2013 | +6.5 pp | DGX |
| FY2012 | +1.9 pp | DGX |
| FY2011 | −2.7 pp | HCA |
| FY2010 | +4.8 pp | DGX |
| FY2009 | +5.1 pp | DGX |
The higher net margin has changed hands between DGX and HCA over this period.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DGX's net margin has been more volatile than HCA's over the 16 comparable fiscal years — 3.0 percentage points of standard deviation against 2.2.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between DGX and HCA over these 16 fiscal years — DGX led in 12 and HCA in 4.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.